Φορτώνει......
Low-dose Naltrexone for the treatment of sarcoidosis
Systemic therapy is administered to 50% of patients and the need for long-term use of therapy is quite variable (1,2). Prednisone is often administered for many months with risk for multiple side effects, immunomodulators as steroid sparing agents have a delayed onset of action and have risks for in...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Sarcoidosis Vasc Diffuse Lung Dis |
|---|---|
| Κύριοι συγγραφείς: | , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Mattioli 1885
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7170144/ https://ncbi.nlm.nih.gov/pubmed/32476841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.36141/svdld.v34i2.5303 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|